Peptide Stack for Over 50: Epithalon, Sermorelin, BPC-157, and GHK-Cu

The peptide landscape for adults over 50 is different in important ways from protocols designed for younger users. The physiological context has changed: growth hormone production has declined by 50–70% compared to youthful levels, telomere length has shortened, tissue repair rates have slowed, and cumulative inflammation ("inflammaging") has set in. The goal shifts from optimization at the margin to meaningful restoration of biological function.

At the same time, the appropriate approach is more conservative. Receptor sensitivity changes with age, the stakes of side effects are higher, and comorbidities or medications introduce more variables. This guide presents a four-peptide longevity-focused stack built for the over-50 population — designed for safety, meaningful impact, and long-term sustainability.

The Biological Targets in the Over-50 Body

To build an effective stack, understand what age-related decline looks like at the cellular level:

Telomere shortening: Each cell division shortens telomeres (the protective caps on chromosomes). When critically short, cells enter senescence (stop dividing) or apoptosis. Senescent cells secrete inflammatory molecules (the senescence-associated secretory phenotype, SASP) that damage neighboring tissue.

Declining growth hormone: GH pulses diminish in frequency and amplitude with age, reducing IGF-1, lean mass, collagen synthesis, and cognitive sharpness.

Mitochondrial decline: Mitochondrial number, efficiency, and quality decline with age, reducing cellular energy production and increasing oxidative stress.

Chronic low-grade inflammation: Elevated baseline IL-6, TNF-α, and CRP are ubiquitous in aging adults and drive progression of cardiovascular disease, neurodegeneration, and metabolic dysfunction.

Tissue repair insufficiency: Slower wound healing, more frequent tendon injuries, cartilage degradation, and skin thinning all reflect declining repair signaling.

A well-designed over-50 stack addresses telomere biology, GH restoration, inflammation, and tissue repair — without overwhelming a system that is less hormonally robust than it was at 30.

Layer 1: Epithalon (Telomere and Longevity Signaling)

Epithalon (also spelled Epitalon) is a tetrapeptide (Ala-Glu-Asp-Gly) developed by the St. Petersburg Institute of Bioregulation and Gerontology under Professor Vladimir Khavinson. It is the most thoroughly researched of the bioregulatory peptides specifically studied for longevity applications.

Its primary mechanisms:

• Telomerase activation: Epithalon is one of the only compounds with published evidence for stimulating telomerase (the enzyme that lengthens telomeres) in human somatic cells. A landmark study by Khavinson et al. demonstrated telomerase activation in human fetal fibroblasts, with implications for cellular rejuvenation.
• Pineal gland support: Epithalon stimulates melatonin production by the pineal gland, restoring the circadian melatonin rhythm that degrades with age — a major driver of sleep quality decline over 50
• Antioxidant activity: Reduces lipid peroxidation and upregulates endogenous antioxidant systems
• Cancer risk modulation: Multiple rodent lifespan studies have shown reduced tumor incidence and increased maximum lifespan with epithalon treatment

Long-term human trials from Russian research institutions followed patients for 6+ years and reported reduced cardiovascular mortality and cancer incidence with epithalon therapy.

Protocol for over 50:

• Dose: 5–10 mg per day (conservative end of the range)
• Administration: Subcutaneous injection
• Timing: Evening (supports melatonin restoration and sleep)
• Cycle: Classic "Khavinson protocol" is 10 days on, twice yearly (spring and fall); alternatively, 4–6 weeks once yearly

This periodic cycling approach mimics how epithalon was studied clinically and avoids any theoretical concerns about sustained telomerase activation.

For more on epithalon's evidence and mechanisms, see our epithalon peptide longevity guide.

Layer 2: Sermorelin (Growth Hormone Restoration)

Sermorelin is a synthetic version of GHRH (1–29) — the first 29 amino acids of the naturally occurring growth hormone-releasing hormone. It was the first GHRH analog approved by the FDA (since withdrawn from the US market but available as a compounded peptide), making it one of the most clinically studied GH-stimulating peptides.

For the over-50 population, sermorelin offers a gentle, physiologically appropriate GH restoration approach:

• Works by stimulating the pituitary to release GH according to its own natural feedback regulation — preventing excessive GH release through intact somatostatin counterregulation
• Produces GH pulses in the normal physiological range (unlike exogenous HGH, which bypasses this regulation)
• Published clinical trials demonstrate improvements in lean body mass, fat mass reduction, skin thickness, and bone density in adults over 50 with GH deficiency

Unlike the CJC-1295 + ipamorelin combination (more appropriate for younger users seeking stronger GH pulses), sermorelin produces a more modest, age-appropriate stimulation that respects the changed pituitary sensitivity of the mature system.

Protocol for over 50:

• Dose: 100–200 mcg (start at 100 mcg for the first 4 weeks)
• Administration: Subcutaneous injection
• Timing: Before sleep — GH pulses predominantly occur during slow-wave sleep
• Cycle: 3–6 months on, 1–2 months off; monitor IGF-1 to titrate dosing
• Target IGF-1: Aim for the upper-normal range for your age group, not the upper limit of young-adult ranges

Layer 3: BPC-157 (Systemic Tissue Maintenance)

BPC-157's role over 50 shifts from acute injury repair to systemic tissue maintenance and anti-inflammatory support. As the body's repair capacity declines, the accumulation of micro-damage in tendons, gut lining, joints, and organ tissue begins to manifest as chronic pain, fatigue, and functional decline.

BPC-157 at maintenance doses provides:

• Continuous support for tendon and joint integrity as training continues past 50
• Gut barrier maintenance, reducing the systemic inflammatory burden from intestinal permeability
• Neurological protection — animal studies show BPC-157 protects dopaminergic neurons and reduces neuroinflammation
• Cardiovascular support — evidence for protection against ischemia-reperfusion injury and cardiac function preservation

The over-50 rationale is preventive and maintenance-oriented rather than acute-repair-oriented.

Protocol for over 50:

• Dose: 250 mcg per day (conservative; well below acute injury dosing)
• Administration: Subcutaneous injection or oral for GI-specific support
• Timing: Morning
• Cycle: Year-round maintenance with a 4-week break every 12–16 weeks is appropriate for long-term use

For the full BPC-157 evidence base, see our BPC-157 guide.

Layer 4: GHK-Cu (Skin, Connective Tissue, and Gene Expression)

GHK-Cu becomes increasingly important over 50 for reasons beyond skin appearance. Research by Dr. Loren Pickart has demonstrated that GHK-Cu modulates the expression of over 4,000 genes in human cells — many of which are associated with inflammation suppression, antioxidant defense, and DNA repair.

For the over-50 body specifically:

• Restores collagen synthesis rates toward younger levels
• Reduces MMP (matrix metalloproteinase) activity that degrades connective tissue
• Exerts anti-inflammatory gene expression effects systemically
• Supports wound healing capacity that declines with age
• Provides visible skin rejuvenation that reflects deeper dermal repair

Protocol for over 50:

• Topical: 1–3% GHK-Cu serum applied daily to face, neck, and hands
• Systemic injectable: Optional 1–2 mg subcutaneous injection 2–3x per week for broader tissue effects
• Timing: Topical can be applied any time; injectable on the same schedule as BPC-157

See our copper peptides complete guide for the full application spectrum.

Conservative Dosing Principles for Over 50

The over-50 protocol uses lower doses and gentler cycling than protocols designed for younger adults. The reasons are physiological, not arbitrary:

• Receptor sensitivity: Receptor populations shift with age; a dose that produces a mild response in a 30-year-old may produce a stronger response in a 60-year-old
• Metabolic clearance: Hepatic and renal clearance of peptides may be slower over 50, extending effective half-lives
• Comorbidity interactions: Medications for blood pressure, cholesterol, diabetes, and thyroid conditions are common over 50. Always review peptide use with your physician in the context of your current medication list.
• Starting principle: Begin each new peptide at the low end of the dose range and observe for 2–4 weeks before increasing

Blood Work Monitoring Protocol

Over-50 peptide use should be supervised by blood work monitoring every 6–12 months:

Baseline panel:

• IGF-1 (tracks GH axis response to sermorelin)
• Comprehensive metabolic panel (kidney and liver function)
• CBC (complete blood count — baseline immune health)
• Lipid panel
• Fasting glucose and HbA1c (GH affects insulin sensitivity)
• PSA (men over 50 — rule out prostate cancer before starting any GH-stimulating protocol)
• Testosterone, free testosterone, estradiol (especially for men on sermorelin)
• TSH, free T3 (thyroid function interacts with GH axis)

At 12–16 weeks:

• IGF-1 (confirm target range)
• Fasting glucose
• PSA (men — sermorelin can modestly increase IGF-1, and IGF-1 sensitivity at the prostate warrants monitoring)

Lifestyle Amplifiers That Matter Most Over 50

The over-50 body responds more dramatically to lifestyle foundations than younger bodies do, for better and worse. The peptide stack's effectiveness multiplies when paired with:

• Resistance training: The single most powerful stimulus for maintaining muscle mass, bone density, and metabolic health after 50. Without it, peptide-driven GH and IGF-1 elevation has less tissue to signal.
• Sleep optimization: GH restoration through sermorelin is maximized with 7–9 hours of quality sleep. Sleep disruption at this age is more pharmacologically resistant — DSIP from our stress and burnout peptide stack can be added if sleep quality is poor.
• Protein intake: Anabolic resistance — the reduced muscle protein synthesis response to amino acids — increases over 50. Compensate with higher protein intake (1.8–2.2 g/kg/day) and emphasis on leucine-rich sources.
• Vitamin D optimization: Target 60–80 ng/mL serum 25-OH vitamin D. Deficiency impairs immune function, muscle performance, and bone density independently.

Frequently Asked Questions

Q: Is epithalon safe for long-term use given its telomerase-activating properties? The primary theoretical concern with telomerase activation is cancer risk — cancer cells often hijack telomerase for immortality. However, epithalon's mechanism appears to reactivate telomerase in the context of normal cellular aging, not oncogenic transformation. The long-term human studies from Russia (6+ years) did not show increased cancer incidence; indeed, some showed reduced rates. The periodic cycling protocol (twice yearly, 10 days each) minimizes exposure while preserving efficacy.

Q: How does sermorelin compare to HGH for over-50 users? Sermorelin is typically preferred for over-50 use because its pituitary-regulated mechanism prevents overshooting natural GH output. Exogenous HGH bypasses all feedback regulation and can produce supraphysiological IGF-1 levels with associated risks (joint pain, fluid retention, potential insulin resistance). Sermorelin achieves meaningful GH restoration with a more favorable safety profile for long-term use.

Q: Should I start all four peptides at once? No. Introduce one peptide at a time over 2–4 week intervals. This allows you to identify any individual reactions and attribute effects clearly. Start with GHK-Cu topically (lowest risk, no injections required), then add BPC-157, then sermorelin, then epithalon during its designated cycle.

Q: Can women over 50 use this stack? Yes, with specific attention to the hormonal context of menopause. Sermorelin is appropriate for postmenopausal women and may complement estrogen replacement therapy. Discuss with your gynecologist or functional medicine physician. GHK-Cu, BPC-157, and epithalon have no sex-specific contraindications.

Q: What results can realistically be expected over the first year? Realistic first-year expectations with consistent use: improved sleep quality and duration (within weeks), improved body composition (reduced fat, maintained or increased lean mass over 6–12 months with exercise), measurable improvements in skin thickness and texture, reduced joint and tendon discomfort, improved energy and cognitive clarity. These are functional quality-of-life improvements — not reversal of 20 years of aging, but meaningful restoration of physiological resilience.